Clostridium butyricum CBM588 Strain

Phase 2Small molecule

Clostridium butyricum CBM588 Strain is one of 5 small molecule programs targeting Renal Cell Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal Cell CancerNot yet recruiting

Renal Cell CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Renal Cell Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

2 2

Yervoy

Bristol-Myers Squibb

Phase 1

2 3

Valemetostat

Bristol-Myers Squibb

Phase 1

1 4

Clostridium butyricum CBM588 Strain

CCity of Hope Medical Center

Phase 2

1 5

Neoadjuvant Nivolumab

TThe Netherlands Cancer Institute

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Renal Cell Cancer

NCT07037004

Clinical

Trials by Indication[1]

Renal Cell Cancer1 trial

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

Not yet recruiting·—·Phase 2·NCT07037004·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Clostridium butyricum CBM588 Strain. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Clostridium butyricum CBM588 Strain compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Clostridium butyricum CBM588 Strain. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — City of Hope Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCity of Hope Medical Center

Clostridium butyricum CBM588 Strain

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Renal Cell Cancer1 trial

References

Drug Info

Quick Facts

Related News